[go: up one dir, main page]

RU2000100362A - APPLICATION OF THE SPECIFIC ANTAGONIST OF 5HT2 RECEPTORS FOR PREPARATION OF MEDICINES SUITABLE FOR THE TREATMENT OF APNEA SYNDROME IN THE SLEEP - Google Patents

APPLICATION OF THE SPECIFIC ANTAGONIST OF 5HT2 RECEPTORS FOR PREPARATION OF MEDICINES SUITABLE FOR THE TREATMENT OF APNEA SYNDROME IN THE SLEEP

Info

Publication number
RU2000100362A
RU2000100362A RU2000100362/14A RU2000100362A RU2000100362A RU 2000100362 A RU2000100362 A RU 2000100362A RU 2000100362/14 A RU2000100362/14 A RU 2000100362/14A RU 2000100362 A RU2000100362 A RU 2000100362A RU 2000100362 A RU2000100362 A RU 2000100362A
Authority
RU
Russia
Prior art keywords
preparation
treatment
sleep
receptors
application
Prior art date
Application number
RU2000100362/14A
Other languages
Russian (ru)
Other versions
RU2218917C2 (en
Inventor
Франсуаз КАТТЕЛЕН
Original Assignee
Санофи-Синтелябо
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9707998A external-priority patent/FR2765107B1/en
Application filed by Санофи-Синтелябо filed Critical Санофи-Синтелябо
Publication of RU2000100362A publication Critical patent/RU2000100362A/en
Application granted granted Critical
Publication of RU2218917C2 publication Critical patent/RU2218917C2/en

Links

Claims (4)

1. Применение 1-(2-фторфенил)-3-(4-гидроксифенил)-проп-2-ен-1-он-O-(2-диметиламиноэтил)-оксима или одной из его фармацевтически приемлемых солей для приготовления лекарств, пригодных для лечения синдрома апноэ во сне.1. The use of 1- (2-fluorophenyl) -3- (4-hydroxyphenyl) prop-2-en-1-one-O- (2-dimethylaminoethyl) oxime or one of its pharmaceutically acceptable salts for the preparation of drugs suitable for the treatment of sleep apnea syndrome. 2 Применение по п.1 гемифумарата (1Z,2Е)-1-(2-фторфенил)-3-(4-гидроксифенил)-проп-2-ен-1-он-O-(2-диметиламиноэтил)-оксима. 2 The use according to claim 1, (1Z, 2E) -1- (2-fluorophenyl) -3- (4-hydroxyphenyl) -prop-2-en-1-one-O- (2-dimethylaminoethyl) oxime hemifumarate. 3. Применение 1-(2-фторфенил)-3-(4-гидроксифенил)-проп-2-ен-1-он-O-(2-диметиламиноэтил)-оксима или одной из его фармацевтически приемлемых солей для приготовления лекарств, пригодных для лечения синдрома обструктивного апноэ-гипопноэ во сне. 3. The use of 1- (2-fluorophenyl) -3- (4-hydroxyphenyl) prop-2-en-1-one-O- (2-dimethylaminoethyl) oxime or one of its pharmaceutically acceptable salts for the preparation of drugs suitable for the treatment of obstructive sleep apnea-hypopnea syndrome. 4. Применение по п.3 гемифумарата (1Z,2Е)-1-(2-фторфенил)-3-(4-гидроксифенил)-проп-2-ен-1-он-O-(2-диметиламиноэтил)-оксима. 4. The use according to claim 3, hemifumarate (1Z, 2E) -1- (2-fluorophenyl) -3- (4-hydroxyphenyl) prop-2-en-1-one-O- (2-dimethylaminoethyl) -oxime.
RU2000100362/14A 1997-06-26 1998-06-02 Application of specific antagonist of 5ht2a-receptors for preparing drugs useful for treatment of sleep apnea syndrome RU2218917C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9707998A FR2765107B1 (en) 1997-06-26 1997-06-26 USE OF A SPECIFIC 5HT2 RECEPTOR ANTAGONIST FOR THE PREPARATION OF MEDICINES USEFUL IN THE TREATMENT OF SLEEP APNEA SYNDROME
FR97/07998 1997-06-26

Publications (2)

Publication Number Publication Date
RU2000100362A true RU2000100362A (en) 2001-10-20
RU2218917C2 RU2218917C2 (en) 2003-12-20

Family

ID=9508467

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2000100362/14A RU2218917C2 (en) 1997-06-26 1998-06-02 Application of specific antagonist of 5ht2a-receptors for preparing drugs useful for treatment of sleep apnea syndrome

Country Status (28)

Country Link
US (1) US6143792A (en)
EP (1) EP1014960B1 (en)
JP (1) JP3503953B2 (en)
KR (1) KR20010014186A (en)
CN (1) CN1154485C (en)
AT (1) ATE232094T1 (en)
AU (1) AU728227B2 (en)
BG (1) BG104038A (en)
BR (1) BR9810337A (en)
CA (1) CA2295119C (en)
CZ (1) CZ291935B6 (en)
DE (1) DE69811248T2 (en)
EE (1) EE9900595A (en)
ES (1) ES2191942T3 (en)
FR (1) FR2765107B1 (en)
HU (1) HU229058B1 (en)
ID (1) ID23799A (en)
IL (1) IL133632A (en)
IS (1) IS2356B (en)
NO (1) NO325520B1 (en)
NZ (1) NZ502495A (en)
PL (1) PL190723B1 (en)
RU (1) RU2218917C2 (en)
SK (1) SK283845B6 (en)
TR (1) TR199903197T2 (en)
TW (1) TW580386B (en)
UA (1) UA59397C2 (en)
WO (1) WO1999000119A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160898B2 (en) * 2001-12-14 2007-01-09 Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
ATE324110T1 (en) 1998-02-27 2006-05-15 Univ Illinois SUBSTANCES WITH SEROTONIN-LIKE EFFECTS FOR THE TREATMENT OF SLEEP APNEA
US20060241164A1 (en) * 1998-02-27 2006-10-26 The Board Of Trustees Of The University Of Illinoi Pharmacological treatment for sleep apnea
FR2787328A1 (en) * 1998-12-22 2000-06-23 Sanofi Sa Treating snoring and high resistance or resistance syndrome in the upper airways, uses 5HT(2A) or 5HT(2A-2C) receptor antagonist, e.g. 1-(2-fluorophenyl)-3-(4-hydroxyphenyl)-prop-2-en-1-one-O-2-(dimethylaminoethyl)-oxime
CA2371822A1 (en) * 1999-03-01 2000-09-08 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
FR2804604B1 (en) * 2000-02-09 2005-05-27 Sanofi Synthelabo USE OF A CENTRAL CANNABINOID RECEPTOR ANTAGONIST FOR THE PREPARATION OF USEFUL DRUGS TO FACILITATE THE STOPPAGE OF TOBACCO CONSUMPTION
KR20050025628A (en) * 2002-07-19 2005-03-14 바이오비트럼 에이비 Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
AU2005319367B2 (en) * 2004-12-20 2012-05-24 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
EP2186511A1 (en) * 2008-11-13 2010-05-19 Sanofi-Aventis Method of treating sleep disorders using eplivanserin
EP2266554A1 (en) * 2009-05-26 2010-12-29 Sanofi-Aventis Method of treating sleep disorders using eplivanserin
WO2010055461A1 (en) * 2008-11-13 2010-05-20 Sanofi-Aventis Method of treating sleep disorders using eplivanserin
WO2010079241A1 (en) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Use of antagonists and/or inverse agonists of cb1 receptors for the preparation of drugs that increase motor neuron excitability
EP2255726A1 (en) 2009-05-26 2010-12-01 Sanofi-Aventis Spectral profile of SWS enhancing drugs
EP2255807A1 (en) 2009-05-26 2010-12-01 Sanofi-Aventis Method of treating sleep disorders using the combination of eplivanserin and zolpidem
EP2269600A1 (en) * 2009-07-02 2011-01-05 Sanofi-Aventis Treatment of sleep disorders using eplivanserin in COPD patients

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2639942B1 (en) * 1988-12-02 1991-03-29 Sanofi Sa OXIMATED PROPENONE ETHERS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EP0449561A3 (en) * 1990-03-29 1992-04-01 Eli Lilly And Company Use of (r)-norfluoxetine in the preparation of a medicament with affinity to 5ht1c receptors
EP0517984A1 (en) * 1991-06-11 1992-12-16 Merrell Dow Pharmaceuticals Inc. Derivatives of amide analogs of certain methano bridged quinolizines
IL103106A (en) * 1991-09-25 1998-06-15 Sanofi Elf Ethers of thienocyclopentanone oximes, their preparation and pharmaceutical compositions containing them
RU2043125C1 (en) * 1992-05-15 1995-09-10 Эдуард Арутюнович Петросян Method for preventing complications induced by non- inhalation type anesthesia

Similar Documents

Publication Publication Date Title
RU2000100362A (en) APPLICATION OF THE SPECIFIC ANTAGONIST OF 5HT2 RECEPTORS FOR PREPARATION OF MEDICINES SUITABLE FOR THE TREATMENT OF APNEA SYNDROME IN THE SLEEP
RU2218917C2 (en) Application of specific antagonist of 5ht2a-receptors for preparing drugs useful for treatment of sleep apnea syndrome
EE9600118A (en) New oral pharmaceutical dosage form
HUP0201623A3 (en) Use of (s,s)reboxetine a selective norepinephrine reuptake inhibitor for the preparation of pharmaceutical compositions treating disorders of the nervous system
EE200200274A (en) Use of a pyrrolidine acetamide derivative in the manufacture of a medicament for the treatment of disorders of the central nervous system, and a pharmaceutical composition
HUP0203312A3 (en) Pharmaceutically active sulfonamide derivatives, process for their preparation, and pharmaceutical compositions and their use
CA2386690A1 (en) Pharmaceutical tramadol salts
CA2364718A1 (en) Monoamine reuptake inhibitors for treatment of cns disorders
EP1426375A3 (en) Analgesic spiroindole derivatives
IL179017A0 (en) Solid oral dosage form comprising valsartan
EE200300167A (en) Amidoalkylpiperidine and Piperazine Derivatives, Pharmaceutical Composition Containing Them, and Use of Compounds for the Treatment of Nervous System Disorders
AU4058000A (en) Aryl and heteroaryl fused aminoalkyl-imidazole derivatives: selective modulatorsof gabaa receptors
BR9809071A (en) Pharmacological agents
EE9700014A (en) New oral dosage form containing the magnesium salt of omeprazole
EE04905B1 (en) Use of Pidasidino [4,5-b] Indole-1-Acetamide Derivatives for the Preparation of Medicines for the Treatment of Disorders Associated with Peripheral Benzodiazepine Receptor Dysfunction
EP1440691A3 (en) Treatment of neurotic disorders
ZA200107143B (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders.
JP2001513504A5 (en)
WO2000048445A3 (en) Pharmaceutical composition containing desoxypeganine for the treatment of nicotine dependence
IL177626A0 (en) Pharmaceutical compositions for treating sleep apnoea
WO2000037068B1 (en) Use of a 5ht2a and 5ht2a/c receptor antagonist for preparing medicines for treating snoring and high resistance syndrome of upper anatomical airways
NO20032006L (en) Use of melagatran for the manufacture of a medicament for the treatment of ischemic disorders
IL150403A0 (en) NOVEL PROCESS FOR THE PREPARATION OF α-(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
IL150402A0 (en) NOVEL PROCESS FOR THE PREPARATION OF α-(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
MXPA01009468A (en) Treatment of pulmonary hypertension.